Zyncof

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritation, which may occur due to a cold. Additionally, it aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating drainage from the bronchial tubes.

Limitations of Use: This medication is intended for symptomatic relief and does not address the underlying causes of cough or respiratory conditions.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 1 teaspoon (5 mL) administered orally every 4 hours. It is important to note that no more than 6 doses should be taken within a 24-hour period. For children under 12 years of age, the use of this medication is not recommended.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of an overdose, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. It is also advised to refrain from using this product for at least two weeks following the discontinuation of an MAOI. Healthcare professionals should be consulted if there is uncertainty regarding the presence of an MAOI in a prescription medication.

Healthcare providers should be consulted prior to use if the patient has a cough that is productive with excessive phlegm or if the cough is chronic, as seen in conditions such as smoking, asthma, chronic bronchitis, or emphysema.

It is imperative that patients adhere strictly to the recommended dosage and not exceed the directed amount while using this product. Should the cough persist for more than seven days, recur, or be accompanied by symptoms such as fever, rash, or a persistent headache, patients are advised to discontinue use and seek medical advice, as these symptoms may indicate a serious underlying condition.

For pregnant or breastfeeding individuals, it is essential to consult a healthcare professional before using this product to ensure safety for both the mother and child.

General precautions include keeping this product out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

In summary, patients should stop using the product and consult a healthcare provider if the cough lasts beyond seven days, returns, or is associated with fever, rash, or persistent headache.

Side Effects

Patients should be aware of several important warnings associated with the use of this medication. It is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, the medication should not be used for at least 2 weeks after discontinuing an MAOI.

Before using this medication, patients should consult a healthcare professional if they have a cough that occurs with excessive phlegm (mucus) or if they have a chronic cough, such as that associated with smoking, asthma, chronic bronchitis, or emphysema.

Patients are advised to discontinue use and seek medical advice if their cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition. Furthermore, pregnant or breastfeeding individuals should consult a healthcare professional prior to use to ensure safety for both the mother and child.

Drug Interactions

The concomitant use of ZYNCOF with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use ZYNCOF while taking an MAOI or for a period of two weeks following the discontinuation of an MAOI. This combination may result in serious interactions that could pose significant health risks. It is essential for healthcare providers to monitor patients closely and consider alternative treatments during this period to avoid potential adverse effects.

Packaging & NDC

Below are the non-prescription pack sizes of Zyncof (dextromethorphan hbr and guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication. For adolescents aged 12 years and older, the recommended dosage is 1 teaspoon (5 mL) every 4 hours, with a maximum of 6 doses in any 24-hour period. Caution is advised to ensure adherence to the dosing guidelines to avoid potential overdose.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with its use during pregnancy and lactation. The safety of this medication in pregnant women has not been established, and therefore, caution is advised.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be aware that the specific symptoms of an overdose may vary depending on the substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where the specific substance is known, targeted therapies may be employed as indicated.

It is essential for healthcare providers to remain vigilant and act swiftly in the management of overdose situations to ensure optimal patient outcomes.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

Serious side effects have been reported voluntarily through various channels, including surveillance programs. Healthcare professionals and patients are encouraged to report any serious adverse events to the designated phone number available on weekdays from 8 AM to 4 PM AST. This reporting contributes to the ongoing monitoring of the product's safety profile.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is crucial for patients to understand the importance of safeguarding their medication to ensure the safety of young children.

In the event of an overdose, healthcare providers should instruct patients to seek medical help immediately or contact a Poison Control Center. Emphasizing the urgency of this action can help mitigate potential risks associated with overdose and ensure prompt medical intervention if necessary.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at a controlled room temperature between 15-30°C (59-86°F). Care should be taken to avoid exposure to excessive heat or humidity, as these conditions may compromise the integrity of the product. Additionally, the product must not be used if the printed security seal is torn, broken, or missing, ensuring that the product remains secure and safe for use.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Zyncof, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)